What happened Shares of the messenger RNA specialist Moderna (NASDAQ: MRNA) were up by a noteworthy 4% as of 12:35 p.m. EDT on Wednesday. While that percentage may not seem like a lot in absolute terms, it actually translates into a whopping $6 billion rise in the biotech's market capitalization.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
- HuffPost Life
If you're questioning your immunity from your COVID shot or if you want to know your status before getting a booster, read this first.
- USA TODAY
So far, 8.8 million Americans have received a booster dose of the Pfizer vaccine. Here’s everything to know about booster doses of all three vaccines.
- Business Insider
The FDA just authorized booster shots of Moderna's and Johnson & Johnson's COVID-19 vaccines and is letting users mix and match shots
The FDA has authorized booster shots for Johnson & Johnson and Moderna's COVID-19 vaccines.
Wall Street has mixed feelings about penny stocks. These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running for the hills, but why? When we say high return potential, we aren’t exaggerating. The bargain price points allow investors to snap up more shares than possible when investing in other more well-known names. What’s more, even what feels like trivial share price appreciation can translate to massive percentage gai
Pfizer and BioNTech say booster shots restored the vaccine's efficacy rate to 95.6%, according to a new clinical trial.
The CDC's influential vaccines advisory committee recommended both Pfizer and Merck’s new pneumococcal vaccines for older adults, surprising analysts.
CDC gathers to discuss which patient groups should get Moderna and J&J COVID-19 vaccine boosters, and Pfizer reports positive results from booster trial
There was a flurry of positive news on vaccine boosters Thursday, as the Centers for Disease Control and Prevention gathered to discuss which patient groups should be eligible for the boosters developed by Moderna and Johnson & Johnson.
- Business Insider
The FDA has approved mix-and-match boosters, allowing fully vaccinated people to get an extra dose of a different COVID-19 vaccine. Here's why.
- Associated Press
U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially. The Food and Drug Administration’s decisions mark a big step toward expanding the U.S. booster campaign, which began with extra doses of the Pfizer vaccine last month. The latest moves would expand by tens of millions the number of Americans eligible for boosters and formally allow “mixing and matching” of shots — making it simpler to get another dose, especially for people who had a side effect from one brand but still want the proven protection of vaccination.
- Business Insider
The results came from Pfizer's late stage COVID-19 booster trial. The results haven't yet been formally published or scrutinized by other experts.
- BuzzFeed News
Many people are now eligible for a COVID-19 vaccine booster shot. Here’s what you need to know about mix-and-match vaccines, boosters, and more.View Entire Post ›
- Good Morning America
COVID-19 vaccine shots for kids ages 5 to 11 may be available as soon as November after Pfizer and BioNTech submitted on Thursday an emergency use authorization to the Food and Drug Administration (FDA). The FDA has scheduled a public hearing on Oct. 26th to examine the request. The companies' authorization request comes just weeks after they announced new clinical trial data showing the vaccine was "safe, well-tolerated and showed robust neutralizing antibody responses" in kids ages 5 to 11.
- CBS News Videos
The Centers for Disease Control and Prevention will review the Food and Drug Administrations's decision to approve booster shots for the Moderna and Johnson and Johnson vaccines, which would allow more than 15 million Americans to get a booster shot. Dr. Dan Barouch, a physician at Beth Israel Deaconess Medical Center in Boston and director at the Center For Virology and Vaccine Research who helped develop the Johnson & Johnson COVID-19 vaccine, joins CBSN to discuss mixing and matching doses.
- CBS News
The CDC must also weigh in before additional doses can be administered nationwide.
- Washington Examiner
FDA authorizes emergency use for Moderna and J&J booster shots and greenlights 'mix and match' doses
The Food and Drug Administration announced on Wednesday that it gave emergency use authorization for booster shots of the Moderna and the Johnson & Johnson COVID-19 vaccines.
- American City Business Journals
The U.S. Food and Drug Administration has given the OK to Covid-19 vaccine "booster" shots made by Cambridge biotech Moderna Inc.
- Motley Fool
Chasing short-term gains is usually not the best strategy in the stock market. Investing in solid companies and holding their shares for a long time is still the best way to grow your capital. However, some companies with a promising future can provide explosive short-term gains too.
Shares of Compass Pathways extended gains early Wednesday after the biotech company received a new patent for its crystalline psilocybin. U.S. listed stock of Compass Pathways (ticker: CMPS) rose 0.6% in premarket trading Wednesday after jumping 7% on Tuesday. This is the first patent for claims covering its Form A hydrate psilocybin, Compass Pathways said in a press release.
The companies said in a press release the trial, which has not been peer-reviewed, tested 10,000 participants aged 16 and older, and found that the booster shot had a favourable safety profile. The trial results come a day after the U.S. Food and Drug Administration authorized booster doses of the COVID-19 vaccines from Moderna Inc and Johnson & Johnson, and said Americans could choose a different shot from their original inoculation as a booster. Dr. Walid Gellad, a professor at University of Pittsburgh's medical school, said there seems to be a benefit of having the third dose in the delta wave for symptomatic COVID-19.
- Madame Noire
Food And Drug Administration Finally Approve COVID-19 Booster Shot For Johnson & Johnson And Moderna Vaccines
Each brand’s vaccine’s booster ramp-up varies because of how each vaccine is made.